Business
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. “We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals,” said
About this update from Lb Pharmaceuticals Inc
[{"type":"image","alt":"LB Pharmaceuticals Inc","displaySize":"","headline":null,"caption":"LB Pharmaceuticals Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.x_fLVJc153Yix9eSgj33w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2","width":300,"height":136}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture.","length":426,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer. “Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a seasoned corporate builder and strategist, driving the implementation of organizational best practices and supporting organizational and cultural growth. We expect both to make strong contributions as we pursue development of LB-102, a novel benzamide for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.”","length":613,"tagName":"p"},{"type":"text","content":"Ms. Rose is a strategic communications executive with deep expertise spanning corporate affairs and investor relations, including external and internal communications, media, patient advocacy, and government affairs. Prior to joining LB Pharmaceuticals, Ms. Rose served as Senior Vice President, Communications and Investor Relations at Lyell Immunopharma where she was a member of the executive leadership team. She held a similar role as Senior Vice President Communications and Chief of Staff at Prothena Corporation plc. Earlier in her career Ms. Rose held positions of increasing responsibility within Johnson & Johnson. Ms. Rose holds a B.A. in International Relations from...